Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""insulin glargine"" wg kryterium: Temat


Tytuł:
Resolution of insulin resistance, lactic acidosis, and decrease in mechanical support requirements in patients post orthotopic heart transplant with the use of long-acting insulin glargine.
Autorzy:
Darwish R; Anesthesiology Institute, Surgical Critical Care Division, Cleveland Clinic Florida, Weston, USA. .
Chen E; Anesthesiology Institute, Surgical Critical Care Division, Cleveland Clinic Florida, Weston, USA.
Minear S; Anesthesiology Institute, Surgical Critical Care Division, Cleveland Clinic Florida, Weston, USA.
Sheffield C; Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic Florida, Weston, USA.
Pokaż więcej
Źródło:
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2024 Feb 16; Vol. 19 (1), pp. 99. Date of Electronic Publication: 2024 Feb 16.
Typ publikacji:
Journal Article
MeSH Terms:
Acidosis, Lactic*/therapy
Insulin Resistance*
Heart Transplantation*
Humans ; Insulin Glargine ; Insulin, Long-Acting ; Retrospective Studies ; Insulin/therapeutic use ; Lactic Acid
Czasopismo naukowe
Tytuł:
Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program.
Autorzy:
Nicholls SJ; Victorian Heart Institute, Monash University, Clayton, VIC, Australia.
Tofé S; Department of Endocrinology and Nutrition, University Hospital Son Espases, Palma, Spain.
le Roux CW; Diabetes Complications Research Centre, Conway Institute, School of Medicine, University College Dublin, Dublin, Ireland.; Diabetes Research Centre, Ulster University, Coleraine, UK.
D'Alessio DA; Division of Endocrinology, Department of Medicine, Duke Molecular Physiology Institute, Duke University, Durham, NC, USA.
Wiese RJ; Eli Lilly and Company, Indianapolis, IN, USA.
Pavo I; Eli Lilly Regional Operations GmbH, Vienna, Austria.
Brown K; Eli Lilly and Company, Indianapolis, IN, USA.
Weerakkody GJ; Eli Lilly and Company, Indianapolis, IN, USA.
Zeytinoglu M; Eli Lilly and Company, Indianapolis, IN, USA.
Romera IC; Eli Lilly and Company, Avda. de La Industria 30, 28108, Alcobendas, Madrid, Spain. romera_.
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2024 Feb 10; Vol. 23 (1), pp. 63. Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Metabolic Syndrome*/diagnosis
Metabolic Syndrome*/drug therapy
Metabolic Syndrome*/epidemiology
Diabetes Mellitus, Type 2*/diagnosis
Diabetes Mellitus, Type 2*/drug therapy
Diabetes Mellitus, Type 2*/epidemiology
Glucagon-Like Peptide-2 Receptor*
Adult ; Humans ; Prevalence ; Insulin Glargine ; Gastric Inhibitory Polypeptide ; Obesity ; Body Weight ; Hypoglycemic Agents/adverse effects
Czasopismo naukowe
Tytuł:
Comparisons of efficacy and safety in insulin glargine and lixisenatide plus glulisine combination therapy with multiple daily injection therapy in Japanese patients with type 2 diabetes.
Autorzy:
Kawaguchi Y; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Miyamoto S; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Hajika Y; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Ashida N; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Masumoto K; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Sawa J; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Hamazaki K; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Kumeda Y; Department of Internal Medicine, Minami Osaka Hospital, Osaka, Japan.
Pokaż więcej
Źródło:
Journal of diabetes investigation [J Diabetes Investig] 2022 Mar; Vol. 13 (3), pp. 505-514. Date of Electronic Publication: 2021 Oct 11.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Diabetes Mellitus, Type 2*/drug therapy
Hypoglycemic Agents*/administration & dosage
Hypoglycemic Agents*/therapeutic use
Insulin Glargine*/adverse effects
Insulin Glargine*/therapeutic use
Blood Glucose ; Blood Glucose Self-Monitoring ; Glycated Hemoglobin/analysis ; Humans ; Insulin/adverse effects ; Insulin/therapeutic use ; Japan ; Peptides
Czasopismo naukowe
Tytuł:
Using real-world evidence data and digital monitoring to analyze the hepatotoxic profiles of biologics across more than two million patients.
Autorzy:
Banerjee P; Institute for Physiology and Science-IT, Charite, University Medicine Berlin, 10115, Berlin, Germany.
Preissner S; Department Oral and Maxillofacial Surgery, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
Preissner R; Institute for Physiology and Science-IT, Charite, University Medicine Berlin, 10115, Berlin, Germany. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Jul 05; Vol. 13 (1), pp. 10878. Date of Electronic Publication: 2023 Jul 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Monoclonal*/therapeutic use
Biological Products*/adverse effects
Humans ; Adalimumab/adverse effects ; Insulin Glargine ; Trastuzumab ; Interferons
Czasopismo naukowe
Tytuł:
The efficacy of insulin degludec and insulin glargine over NPH insulin among toddlers and preschoolers with type 1 diabetes using glycemic variability and time in range.
Autorzy:
Elhabashy SA; Pediatrics Department, Ain Shams University, Cairo, Egypt.
Sakr EM; Pediatrics Department, Ain Shams University, Cairo, Egypt.
Salah NY; Pediatrics Department, Ain Shams University, Cairo, Egypt. .
Pokaż więcej
Źródło:
European journal of pediatrics [Eur J Pediatr] 2023 Apr; Vol. 182 (4), pp. 1857-1868. Date of Electronic Publication: 2023 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Diabetes Mellitus, Type 1*/drug therapy
Hypoglycemia*/chemically induced
Hypoglycemia*/drug therapy
Humans ; Child, Preschool ; Insulin Glargine/adverse effects ; Insulin, Isophane/therapeutic use ; Hypoglycemic Agents/adverse effects ; Glycated Hemoglobin ; Blood Glucose Self-Monitoring ; Blood Glucose ; Insulin/adverse effects
Czasopismo naukowe
Tytuł:
Caveolin-1 Is Essential for the Improvement of Insulin Sensitivity through AKT Activation during Glargine Treatment on Diabetic Mice.
Autorzy:
Peng H; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.; Ward 2 of Coronary Heart Diseases Centre, Fuwai Yunnan Cardiovascular Hospital, Kunming 650000, China.
Mu P; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Li H; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Lin S; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Lin C; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Lin K; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Liu K; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Zeng W; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Zeng L; Department of Endocrinology and Metabolism, Guangdong Provincial Key Laboratory of Diabetology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.
Pokaż więcej
Źródło:
Journal of diabetes research [J Diabetes Res] 2021 Dec 07; Vol. 2021, pp. 9943344. Date of Electronic Publication: 2021 Dec 07 (Print Publication: 2021).
Typ publikacji:
Journal Article
MeSH Terms:
Caveolin 1/*metabolism
Insulin Glargine/*pharmacology
Insulin Resistance/*genetics
Animals ; Disease Models, Animal ; Insulin Glargine/metabolism ; Insulin Resistance/physiology ; Mice ; Mice, Inbred NOD
Czasopismo naukowe
Tytuł:
Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
Autorzy:
Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang, Malaysia.
Wladysiuk M; Chair of Epidemiology and Preventive Medicine, Medical College, Jagiellonian University, Krakow, Poland.; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland.
McTaggart S; Public Health Scotland, Gyle Square, 1 South Gyle Crescent, Edinburgh, UK.
Kurdi A; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Division of Public Health Pharmacy and Management, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Department of Pharmacology, College of Pharmacy, Hawler Medical University, Erbil, Iraq.
Allocati E; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy.
Jakovljevic M; Department of Global Health Economics and Policy, University of Kragujevac, Kragujevac, Serbia.; Institute of Comparative Economic Studies, Faculty of Economics, Hosei University Tokyo, Tokyo, Japan.
Kalemeera F; Department of Pharmacy Practice and Policy, Faculty of Health Sciences, University of Namibia, Windhoek, Namibia.
Hoxha I; Department of Pharmacy, Faculty of Medicine, University of Medicine, Tirana, Albania.
Nachtnebel A; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Sauermann R; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Hinteregger M; Dachverband der Österreichischen Sozialversicherungen, Kundmanngasse 21, AT-1030 Vienna, Austria.
Marković-Peković V; Faculty of Medicine, Department of Social Pharmacy, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.
Tubic B; Faculty of Medicine, Department of Medicinal Chemistry, University of Banja Luka, Banja Luka, Bosnia and Herzegovina.; Agency for Medicinal Product and Medical Devices of Bosnia and Herzegovina, 78000 Banja Luka, Bosnia and Herzegovina.
Petrova G; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria.
Tachkov K; Faculty of Pharmacy, Department of Social Pharmacy and Pharmacoeconomics, Medical University of Sofia, Sofia, Bulgaria.
Slabý J; State Institute for Drug Control, Prague, Czech Republic.
Nejezchlebova R; State Institute for Drug Control, Prague, Czech Republic.
Krulichová IS; Department of Medical Biophysics, Faculty of Medicine in Hradec Králové, Charles University, Simkova 870, 500 03 Hradec Králové, Czech Republic.
Laius O; State Agency of Medicines, Nooruse 1, 50411 Tartu, Estonia.
Selke G; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany.
Langner I; Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178 Berlin, Germany.
Harsanyi A; Department of Health Policy and Health Economics, Eotvos Lorand University, Budapest, Hungary.
Inotai A; Syreon Research Institute and Semmelweis University, Center of Health Technology Assessment, Budapest, Hungary.
Jakupi A; Faculty of Pharmacy, UBT Higher Education Institute, Pristina, Kosovo.
Henkuzens S; Independent Consultant, Riga, Latvia.
Garuolienė K; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Gulbinovič J; Department of Pathology, Forensic Medicine and Pharmacology, Institute of Biomedical Sciences, Faculty of Medicine, Vilnius University, Vilnius, Lithuania.
Bonanno PV; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK.; Department of Health Services Management, University of Malta, Valletta, Malta.
Rutkowski J; HTA Consulting, Starowiślna Str. 17/3, 31-038 Krakow, Poland.
Ingeberg S; Medicines Committee, Oslo University Hospitals, Oslo, Norway.
Melien Ø; Medicines Committee, Oslo University Hospitals, Oslo, Norway.
Mardare I; Faculty of Medicine, Public Health and Management Department, 'Carol Davila' University of Medicine and Pharmacy Bucharest, 050463 Bucharest, Romania.
Fürst J; Health Insurance Institute, Miklosiceva 24, SI-1507 Ljubljana, Slovenia.
MacBride-Stewart S; Pharmacy Services, Greater Glasgow and Clyde (NHS GGC), Glasgow, UK.
Holmes C; NHS Lothian, Edinburgh, UK.
Pontes C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.; Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, Barcelona, Spain.
Zara C; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.
Pedrola MT; Drug Department, Catalan Health Service, Gran Via de les Corts Catalanes, 08007 Barcelona, Spain.
Hoffmann M; NEPI-Nätverk för läkemedelsepidemiologi, Stockholm, Sweden.
Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece.
Pisana A; Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Banzi R; Istituto di Ricerche Farmacologiche 'Mario Negri' IRCCS, Milan, Italy.
Campbell S; Centre for Primary Care and Health Services Research, School of Health Sciences, University of Manchester, Manchester M13 9PL, UK.; NIHR Greater Manchester Patient Safety Translational Research Centre, School of Health Sciences, University of Manchester, Manchester, UK.
Wettermark B; Department of Pharmacy, Disciplinary Domain of Medicine and Pharmacy, Uppsala University, Uppsala, Sweden.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2021 Oct 11; Vol. 2021, pp. 9996193. Date of Electronic Publication: 2021 Oct 11 (Print Publication: 2021).
Typ publikacji:
Journal Article
MeSH Terms:
Biosimilar Pharmaceuticals/*therapeutic use
Cost-Benefit Analysis/*trends
Diabetes Mellitus/*drug therapy
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*therapeutic use
Insulin, Long-Acting/*therapeutic use
Patient Education as Topic/*methods
Biosimilar Pharmaceuticals/economics ; Diabetes Mellitus/diagnosis ; Diabetes Mellitus/economics ; Europe ; Humans ; Hypoglycemic Agents/economics ; Insulin Glargine/economics ; Insulin, Long-Acting/economics
Czasopismo naukowe
Tytuł:
Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta-analysis.
Autorzy:
Xu J; Department of Endocrinology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.
Yao D; Department of Endocrinology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.
Xia J; Department of Endocrinology, HwaMei Hospital, University of Chinese Academy of Sciences, Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo, China.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2021 Oct; Vol. 46 (5), pp. 1245-1253. Date of Electronic Publication: 2021 Mar 06.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Diabetes Mellitus, Type 2/*drug therapy
Glucagon-Like Peptides/*analogs & derivatives
Immunoglobulin Fc Fragments/*therapeutic use
Insulin Glargine/*therapeutic use
Recombinant Fusion Proteins/*therapeutic use
Drug Administration Schedule ; Glucagon-Like Peptides/adverse effects ; Glucagon-Like Peptides/therapeutic use ; Glycated Hemoglobin ; Humans ; Hypoglycemia/chemically induced ; Immunoglobulin Fc Fragments/adverse effects ; Insulin Glargine/adverse effects ; Randomized Controlled Trials as Topic ; Recombinant Fusion Proteins/adverse effects ; Weight Gain ; Weight Loss
Czasopismo naukowe
Tytuł:
Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studies.
Autorzy:
Sun B; Viatris Inc, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA. .
Sengupta N; Biocon Research Limited, 20th KM, Hosur Road, Electronic City, 560100, Bangalore, India.
Rao A; Biocon Research Limited, 20th KM, Hosur Road, Electronic City, 560100, Bangalore, India.
Donnelly C; Viatris Inc, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA.
Waichale V; Biocon Research Limited, 20th KM, Hosur Road, Electronic City, 560100, Bangalore, India.; Agilex Biolabs, SA, Thebarton, Australia.
Roy AS; Biocon Research Limited, 20th KM, Hosur Road, Electronic City, 560100, Bangalore, India.; Cliantha Research Limited, Ahmedabad, India.
Ramaswamy S; Biocon Research Limited, 20th KM, Hosur Road, Electronic City, 560100, Bangalore, India.
Pathak D; Biocon Research Limited, 20th KM, Hosur Road, Electronic City, 560100, Bangalore, India.; Altasciences, QC, Laval, Canada.
Bowsher RR; B2S Life Sciences, 97 East Monroe Street, Franklin, IN, 46131, USA.
Raiter Y; Viatris Inc, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA.
Aubonnet P; Viatris Inc, Turmstrasse 24, Tower 4, 6312, Steinhausen, Switzerland.
Barve A; Viatris Inc, 1000 Mylan Boulevard, Canonsburg, PA, 15317, USA.
Pokaż więcej
Źródło:
BMC endocrine disorders [BMC Endocr Disord] 2021 Jun 26; Vol. 21 (1), pp. 129. Date of Electronic Publication: 2021 Jun 26.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
MeSH Terms:
Diabetes Mellitus, Type 1/*drug therapy
Diabetes Mellitus, Type 2/*drug therapy
Hypoglycemic Agents/*therapeutic use
Immunogenetic Phenomena/*drug effects
Insulin Glargine/*therapeutic use
Adult ; Biosimilar Pharmaceuticals/pharmacology ; Biosimilar Pharmaceuticals/therapeutic use ; Diabetes Mellitus, Type 1/blood ; Diabetes Mellitus, Type 1/immunology ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/immunology ; Female ; Humans ; Hypoglycemic Agents/pharmacology ; Immunogenetic Phenomena/physiology ; Insulin Glargine/pharmacology ; Male ; Middle Aged
Czasopismo naukowe
Tytuł:
Renal hemodynamic effects differ between antidiabetic combination strategies: randomized controlled clinical trial comparing empagliflozin/linagliptin with metformin/insulin glargine.
Autorzy:
Ott C; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.; Department of Nephrology and Hypertension, Paracelsus Medical University, Nuremberg, Germany.
Jung S; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.; Department of Cardiology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Korn M; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.
Kannenkeril D; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.
Bosch A; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.
Kolwelter J; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.; Department of Cardiology, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany.
Striepe K; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.
Bramlage P; Institute for Pharmacology and Preventive Medicine, Cloppenburg, Germany.
Schiffer M; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany.
Schmieder RE; Department of Nephrology and Hypertension, Friedrich-Alexander University Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany. .
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2021 Sep 04; Vol. 20 (1), pp. 178. Date of Electronic Publication: 2021 Sep 04.
Typ publikacji:
Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Benzhydryl Compounds/*therapeutic use
Diabetes Mellitus, Type 2/*drug therapy
Diabetic Nephropathies/*prevention & control
Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
Glucosides/*therapeutic use
Hemodynamics/*drug effects
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*therapeutic use
Linagliptin/*therapeutic use
Metformin/*therapeutic use
Renal Plasma Flow/*drug effects
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Aged ; Benzhydryl Compounds/adverse effects ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnosis ; Diabetic Nephropathies/diagnosis ; Diabetic Nephropathies/etiology ; Diabetic Nephropathies/physiopathology ; Dipeptidyl-Peptidase IV Inhibitors/adverse effects ; Drug Therapy, Combination ; Female ; Germany ; Glomerular Filtration Rate/drug effects ; Glucosides/adverse effects ; Humans ; Hypoglycemic Agents/adverse effects ; Insulin Glargine/adverse effects ; Linagliptin/adverse effects ; Male ; Metformin/adverse effects ; Middle Aged ; Prospective Studies ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Fasting Glucose of 6.1 mmol/L as a Possible Optimal Target for Type 2 Diabetic Patients with Insulin Glargine: A Randomized Clinical Trial.
Autorzy:
Yuan L; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Li F; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zhou Y; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.; Department of Endocrinology, The First People's Hospital of Huaian, Huaian, China.
Sun R; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Gao G; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Zhang Q; Department of Endocrinology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, China.
Tang Y; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Dai L; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Wu J; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Ma J; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.
Pokaż więcej
Źródło:
Journal of diabetes research [J Diabetes Res] 2021 Jul 14; Vol. 2021, pp. 5524313. Date of Electronic Publication: 2021 Jul 14 (Print Publication: 2021).
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Blood Glucose/*analysis
Diabetes Mellitus, Type 2/*drug therapy
Fasting/*blood
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*therapeutic use
Adult ; Aged ; Blood Glucose Self-Monitoring ; Diabetes Mellitus, Type 2/blood ; Female ; Glycated Hemoglobin/analysis ; Humans ; Insulin Glargine/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Weight Gain
Czasopismo naukowe
Tytuł:
Use of basal insulin in the management of adults with type 2 diabetes: An Asia-Pacific evidence-based clinical practice guideline.
Autorzy:
Ji L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Luo Y; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Bee YM; Department of Endocrinology, Singapore General Hospital, Singapore, Singapore.
Xia J; Nottingham Ningbo GRADE Centre, University of Nottingham Ningbo China, Zhejiang, China.; Academic Unit of Lifespan and Population Health, School of Medicine, The University of Nottingham, Nottingham, UK.
Nguyen KT; Ho Chi Minh University of Medicine and Pharmacy Medic Medical Center, Ho Chi Minh City, Vietnam.
Zhao W; Department of Endocrinology, Peking Union Medical College Hospital, Beijing, China.
Chen L; Chu Hsien-I Memorial (Metabolic Diseases) Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, China.
Chan SP; Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Deerochanawong C; College of Medicine, Rangsit University, Bangkok, Thailand.
Lim S; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, South Korea.
Yabe D; Departments of Diabetes, Endocrinology and Metabolism/Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.; Center for One Medicine Innovative Translational Research, Gifu University Institute for Advanced Study, Gifu, Japan.
McGill M; Diabetes Centre, Royal Prince Alfred Hospital, Faculty of Medicine and Health University of Sydney, Sydney, Australia.
Suastika K; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Udayana University, Prof. IGNG Ngoerah Hospital, Denpasar, Indonesia.
Li X; Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, China.
Kong APS; Division of Endocrinology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, China.
Chen W; Department of Clinical Nutrition, Department of Health Medicine, Chinese Academy of Medical Sciences-Peking Union Medical College, Peking Union Medical College Hospital, Beijing, China.
Zhao Z; Tianjin Tiantian Biotechnology Co., Ltd, Tianjin, China.
Xu C; Tianjin Tiantian Biotechnology Co., Ltd, Tianjin, China.
Deodat M; Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, Canada.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
Yao X; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.; Center for Clinical Practice Guideline Conduction and Evaluation, Children's Hospital of Fudan University, Shanghai, China.
Pokaż więcej
Źródło:
Journal of diabetes [J Diabetes] 2023 Jun; Vol. 15 (6), pp. 474-487. Date of Electronic Publication: 2023 Apr 23.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Diabetes Mellitus, Type 2*/drug therapy
Humans ; Adult ; Insulin Glargine ; Insulin ; Insulin, Long-Acting ; Asia
Czasopismo naukowe
Tytuł:
Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta-analysis.
Autorzy:
Luo Y; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Xia J; Nottingham Ningbo GRADE Centre, University of Nottingham Ningbo China, Ningbo, Zhejiang, 315100, China.; Academic Unit of Lifespan and Population Health, School of Medicine, The University of Nottingham, Nottingham, NG7 2UH, UK.
Zhao Z; Tianjin Tiantian Biotechnology Co., Ltd., Tianjin, 300000, China.
Chang Y; OrthoEvidence Inc., Burlington, Ontario, L7N 3H8, Canada.
Bee YM; Department of Endocrinology, Singapore General Hospital, 169608, Singapore, Singapore.
Nguyen KT; Ho Chi Minh University of Medicine and Pharmacy Medic Medical Center, Ho Chi Minh City, 700000, Vietnam.
Lim S; Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Bundang Hospital, Seongnam, 13620, South Korea.
Yabe D; Departments of Diabetes, Endocrinology and Metabolism/Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, 501-1194, Japan.; Center for One Medicine Innovative Translational Research, Gifu University Institute for Advanced Study, Gifu, 501-1194, Japan.
McGill M; Diabetes Centre, Royal Prince Alfred Hospital, Faculty of Medicine and Health University of Sydney, Sydney, New South Wales, 2050, Australia.
Kong APS; Division of Endocrinology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, Hong Kong, 999077, China.
Chan SP; Subang Jaya Medical Centre, Department of Medicine, University of Malaya Medical Centre, Lembah Pantai, Kuala Lumpur, 59100, Malaysia.
Deodat M; Michael G. DeGroote Cochrane Canada and McMaster GRADE Centres, McMaster University, Hamilton, Ontario, L8V 5C2, Canada.
Deerochanawong C; College of Medicine, Rangsit University, Bangkok, 10400, Thailand.
Suastika K; Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine, Udayana University, Prof. IGNG Ngoerah Hospital, Denpasar, Bali, 80114, Indonesia.
Xu C; Tianjin Tiantian Biotechnology Co., Ltd., Tianjin, 300000, China.
Chen L; Chu Hsien-I Memorial (Metabolic Diseases) Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin, 300134, China.
Chen W; Department of Clinical Nutrition, Department of Health Medicine, Chinese Academy of Medical Sciences-Peking Union Medical College, Peking Union Medical College Hospital, Beijing, 100730, China.
Li X; Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Zhao W; Department of Endocrinology, Peking Union Medical College Hospital, Beijing, 100730, China.
Yao X; Center for Clinical Practice Guideline Conduction and Evaluation, Children's Hospital of Fudan University, Shanghai, 201100, China.; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, L8V 5C2, Canada.
Ji L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, 100044, China.
Pokaż więcej
Źródło:
Journal of diabetes [J Diabetes] 2023 May; Vol. 15 (5), pp. 419-435. Date of Electronic Publication: 2023 Apr 10.
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Diabetes Mellitus, Type 2*/drug therapy
Hypoglycemia*
Humans ; Insulin Glargine/therapeutic use ; Insulin, Long-Acting/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Insulin Detemir/therapeutic use ; Insulin, Isophane
Czasopismo naukowe
Tytuł:
Physicochemical and functional characterization of MYL-1501D, a proposed biosimilar to insulin glargine.
Autorzy:
Goyal P; Viatris Inc, Canonsburg, PA, United States of America.
Pai HV; Biocon Research Limited, Bangalore, India.
Kodali P; Biocon Research Limited, Bangalore, India.
Vats B; Viatris Inc, Hyderabad, India.
Vajpai N; Biocon Research Limited, Bangalore, India.
Annegowda S; Biocon Research Limited, Bangalore, India.
Mane K; Biocon Research Limited, Bangalore, India.
Mohan S; Biocon Research Limited, Bangalore, India.
Saxena S; Biocon Research Limited, Bangalore, India.
Veerabhadraia AB; Biocon Research Limited, Bangalore, India.
Palande M; Biocon Research Limited, Bangalore, India.
Nair PS; Biocon Research Limited, Bangalore, India.
More DC; Biocon Research Limited, Bangalore, India.
Karudumpa UR; Biocon Research Limited, Bangalore, India.
Jyothirmai K; Biocon Research Limited, Bangalore, India.
Bhattacharya A; Biocon Research Limited, Bangalore, India.
Almeida F; Biocon Research Limited, Bangalore, India.
Khyade SG; Biocon Research Limited, Bangalore, India.
Gouda S; Viatris Inc, Hyderabad, India.
Ranayhossaini DJ; Viatris Inc, Canonsburg, PA, United States of America.
Moole PR; Biocon Research Limited, Bangalore, India.
Smith JP; Viatris Inc, Canonsburg, PA, United States of America.
Barve A; Viatris Inc, Canonsburg, PA, United States of America.
Melarkode R; Biocon Research Limited, Bangalore, India.
Ullanat R; Viatris Inc, Hyderabad, India.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2021 Jun 16; Vol. 16 (6), pp. e0253168. Date of Electronic Publication: 2021 Jun 16 (Print Publication: 2021).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Insulin Glargine/*chemistry
3T3 Cells ; Adipogenesis/drug effects ; Amino Acid Sequence ; Animals ; Biosimilar Pharmaceuticals/chemistry ; Biosimilar Pharmaceuticals/pharmacology ; CHO Cells ; Circular Dichroism ; Cricetulus ; Gas Chromatography-Mass Spectrometry ; Glucose/metabolism ; Humans ; Insulin Glargine/pharmacology ; Lipolysis/drug effects ; Magnetic Resonance Spectroscopy ; Mice ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Rabbits ; Spectroscopy, Fourier Transform Infrared
Czasopismo naukowe
Tytuł:
A randomized trial to investigate the efficacy and safety of insulin glargine in hyperglycemic acute stroke patients receiving intensive care.
Autorzy:
Tang SC; Stroke Center and Department of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan.
Shih SR; Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan.
Lin SY; Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan.; School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.
Chen CH; Stroke Center and Department of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan.
Yeh SJ; Stroke Center and Department of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan.
Tsai LK; Stroke Center and Department of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan.
Yang WS; Department of Internal Medicine, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan. .; Graduate Institute of Clinical Medicine, National Taiwan University, Taipei, Taiwan. .
Jeng JS; Stroke Center and Department of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, 10055, Taiwan. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2021 Jun 01; Vol. 11 (1), pp. 11523. Date of Electronic Publication: 2021 Jun 01.
Typ publikacji:
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:
Critical Care*
Hypoglycemia*/blood
Hypoglycemia*/complications
Hypoglycemia*/drug therapy
Stroke*/blood
Stroke*/complications
Stroke*/drug therapy
Insulin Glargine/*administration & dosage
Acute Disease ; Aged ; Aged, 80 and over ; Blood Glucose/metabolism ; Female ; Humans ; Insulin Glargine/adverse effects ; Male ; Middle Aged ; Pilot Projects
Czasopismo naukowe
Tytuł:
The vascular function effects of adding exenatide or meal insulin to basal insulin therapy in early type 2 diabetes.
Autorzy:
Retnakaran R; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada. .; Division of Endocrinology, University of Toronto, 60 Murray Street, Suite L5-025, Toronto, ON, M5T 3L9, Canada. .; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada. .
Pu J; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.
Ye C; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.
Emery A; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.
Kramer CK; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.; Division of Endocrinology, University of Toronto, 60 Murray Street, Suite L5-025, Toronto, ON, M5T 3L9, Canada.; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
Zinman B; Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Canada.; Division of Endocrinology, University of Toronto, 60 Murray Street, Suite L5-025, Toronto, ON, M5T 3L9, Canada.; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada.
Pokaż więcej
Źródło:
Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Mar 09; Vol. 22 (1), pp. 50. Date of Electronic Publication: 2023 Mar 09.
Typ publikacji:
Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Diabetes Mellitus, Type 2*/diagnosis
Diabetes Mellitus, Type 2*/drug therapy
Adult ; Humans ; Insulin/adverse effects ; Exenatide/adverse effects ; Insulin Glargine/adverse effects ; Insulin Lispro/adverse effects ; Hypoglycemic Agents/adverse effects ; Insulin, Long-Acting ; Blood Glucose
Czasopismo naukowe
Tytuł:
Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
Autorzy:
Luo M; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Kong X; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Wang H; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Zhai X; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Cai T; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Ding B; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Hu Y; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Jing T; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Su X; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Li H; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Ma J; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210012, China.
Pokaż więcej
Źródło:
Journal of diabetes research [J Diabetes Res] 2020 Nov 24; Vol. 2020, pp. 6666403. Date of Electronic Publication: 2020 Nov 24 (Print Publication: 2020).
Typ publikacji:
Controlled Clinical Trial; Journal Article
MeSH Terms:
Glycemic Control*/adverse effects
Benzhydryl Compounds/*therapeutic use
Blood Glucose/*drug effects
Diabetes Mellitus, Type 2/*drug therapy
Glucosides/*therapeutic use
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*therapeutic use
Insulin-Secreting Cells/*drug effects
Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use
Aged ; Benzhydryl Compounds/adverse effects ; Biomarkers/blood ; Blood Glucose/metabolism ; C-Peptide/blood ; China ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/diagnosis ; Drug Therapy, Combination ; Female ; Glucosides/adverse effects ; Glycated Hemoglobin/metabolism ; Humans ; Hypoglycemic Agents/adverse effects ; Insulin Glargine/adverse effects ; Insulin-Secreting Cells/metabolism ; Male ; Middle Aged ; Prospective Studies ; Sodium-Glucose Transporter 2 Inhibitors/adverse effects ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Autorzy:
Wolnik B; Medical University of Gdansk, Department of Hypertension and Diabetology, Gdansk, Poland.
Wiza D; Poznan University of Medical Sciences, Department of Internal Medicine and Diabetology, Poznan, Poland.
Szczepanik T; Starkiewicz Hospital, Zaglebie Oncology Center, Dabrowa Gornicza, Poland.
Syta A; Sanofi-Aventis Poland, Medical Affairs, Warszawa, Poland.
Klupa T; Jagiellonian University Medical College, Department of Metabolic Diseases, Kraków, Poland.
Pokaż więcej
Źródło:
Journal of diabetes research [J Diabetes Res] 2020 Apr 08; Vol. 2020, pp. 8751348. Date of Electronic Publication: 2020 Apr 08 (Print Publication: 2020).
Typ publikacji:
Journal Article; Multicenter Study; Observational Study
MeSH Terms:
Glycemic Control*
Blood Glucose/*metabolism
Diabetes Mellitus, Type 2/*drug therapy
Hypoglycemia/*chemically induced
Hypoglycemic Agents/*therapeutic use
Insulin Glargine/*therapeutic use
Insulin, Isophane/*therapeutic use
Aged ; Diabetes Mellitus, Type 2/blood ; Drug Substitution ; Female ; Glycated Hemoglobin/metabolism ; Humans ; Hypoglycemia/blood ; Hypoglycemic Agents/adverse effects ; Insulin Glargine/adverse effects ; Insulin, Isophane/adverse effects ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł:
The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus.
Autorzy:
Wang J; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Li HQ; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Xu XH; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Kong XC; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Sun R; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Jing T; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Ye L; National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore.
Su XF; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Ma JH; Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China.
Pokaż więcej
Źródło:
BioMed research international [Biomed Res Int] 2019 Dec 24; Vol. 2019, pp. 2682657. Date of Electronic Publication: 2019 Dec 24 (Print Publication: 2019).
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms:
Diabetes Mellitus, Type 2/*drug therapy
Glucagon-Like Peptides/*analogs & derivatives
Hypoglycemia/*drug therapy
Immunoglobulin Fc Fragments/*administration & dosage
Insulin Glargine/*administration & dosage
Recombinant Fusion Proteins/*administration & dosage
Aged ; Blood Glucose/drug effects ; Blood Glucose Self-Monitoring/methods ; Diabetes Mellitus, Type 2/genetics ; Diabetes Mellitus, Type 2/pathology ; Dinoprost/genetics ; Drug Therapy, Combination/adverse effects ; Female ; Gene Expression Regulation/drug effects ; Glucagon-Like Peptides/administration & dosage ; Glucagon-Like Peptides/adverse effects ; Glucose/metabolism ; Glycated Hemoglobin/genetics ; Humans ; Hypoglycemia/genetics ; Hypoglycemia/pathology ; Immunoglobulin Fc Fragments/adverse effects ; Insulin Glargine/adverse effects ; Interleukin-6/genetics ; Male ; Metformin/administration & dosage ; Middle Aged ; Recombinant Fusion Proteins/adverse effects ; Tumor Necrosis Factor-alpha/genetics
Czasopismo naukowe
Tytuł:
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
Autorzy:
Russel-Szymczyk M; Novo Nordisk Pharma Sp. z o.o, Warsaw, Poland. .
Valov V; Novo Nordisk Pharma EAD, Sofia, Bulgaria.
Savova A; Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria.
Manova M; Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria.
Pokaż więcej
Źródło:
BMC endocrine disorders [BMC Endocr Disord] 2019 Dec 03; Vol. 19 (1), pp. 132. Date of Electronic Publication: 2019 Dec 03.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Cost-Benefit Analysis*
Diabetes Mellitus, Type 1/*drug therapy
Diabetes Mellitus, Type 2/*drug therapy
Insulin Glargine/*therapeutic use
Insulin, Long-Acting/*therapeutic use
Adult ; Aged ; Biosimilar Pharmaceuticals/economics ; Bulgaria/epidemiology ; Health Care Costs ; Humans ; Hypoglycemia/epidemiology ; Hypoglycemic Agents/therapeutic use ; Insulin Glargine/economics ; Insulin, Long-Acting/economics ; Middle Aged ; Treatment Outcome
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies